Skip to main content

Advertisement

SpringerLink
Log in

Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

Both CD34 (cluster of differentiation 34) and the more recently described CD133 are markers of primitive stem cells with haematopoietic repopulating ability. Most transplanting centres use a minimum number of CD34+ cells as the requirement for a transplant and consider this a predictor of haematopoietic engraftment. However, transplanted CD34+ cell dose does not always give a close correlation with time to engraftment nor explain delayed engraftment in some patients. We have retrospectively evaluated the potential of measuring viable CD133+ cell numbers in the autograft as an alternative predictor of haematological engraftment after autologous stem-cell transplantation in a cohort of patients with multiple myeloma (MM). We found an average 32% loss of viability of CD34+ cells in the post-thaw sample compared with the fresh sample. Of the original estimated CD34+ cell numbers transplanted per kg, 43% of the thawed samples were double positive for CD34+/CD133+. In this patient group, the CD34+/CD133+ subset gave the closest statistical correlation with time to neutrophil engraftment (p < 0.05), particularly for patients given above median (1.8 × 106/kg) dose of the double-positive cells. The CD34+/CD133+ population was the only parameter to give a significant correlation with white cell engraftment in this patient cohort (p < 0.05). There was no significant correlation between CD34+, viable CD34+ or viable CD34+/CD133+ cells/kilogram with platelet engraftment. Determination of viable CD34+/CD133+ progenitor cell dose in the autograft may be a useful tool to predict neutrophil recovery after autologous transplantation than conventional assessment of CD34+ numbers. These results warrant further investigation of the role of CD133 in haematopoietic engraftment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. To LB, Haycock DN, Simmons PJ, Juttner CA (1997) The biology and clinical uses of blood stem cells. Blood 89:2233–2258

    PubMed  CAS  Google Scholar 

  2. Bender JG, To LB, Williams S, Schwartzberg LS (1992) Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1:329–341

    PubMed  CAS  Google Scholar 

  3. Villalon L, Odriozola J, Larana JG, Zamora C, Perez de Oteyza J, Jodra MH et al (2000) Autologous peripheral blood progenitor cell transplantation with <2 × 10(6) CD34 (+)/kg: an analysis of variables concerning mobilisation and engraftment. Hematol J 1:374–381

    Article  PubMed  CAS  Google Scholar 

  4. Shpall EJ, Champlin R, Glaspy JA (1998) Effect of CD34+ peripheral blood progenitor cell dose on haematopoietic recovery. Biol Blood Marrow Transplant 4:84–92

    Article  PubMed  CAS  Google Scholar 

  5. Sator M, Antonenas V, Garvan F, Webb M, Bradstock KF (2005) Recovery of viable CD34+ cells from cryopreserved hemopoietic progenitor cell products. Bone Marrow Transplant 36:199–204

    Article  Google Scholar 

  6. Abrahamsen JF, Wentzel-Larsen T and Bruserud O (2004) Autologous transplantation: the viable transplanted CD34+ cell dose measured post-thaw does not predict engraftment kinetics better than the total CD34+ cell dose measured pre-freeze in patients that receive more than 2 × 10(6) CD34+ cells/kg. Cytotherapy 6:356–362

    Google Scholar 

  7. Allan DS, Keeney M, Howson-Jan K, Popma J, Weir K, Bhatia M, Sutherland DR et al (2002) Number of viable CD34+ cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation. Bone Marrow Transplant 29:967–972

    Article  PubMed  CAS  Google Scholar 

  8. Pecora AL, Preti RA, Gleim GW, Jennis A, Zahos K, Cantwell S et al (1998) CD34+CD33− cells influence days to engraftment and transfusion requirements in autologous blood stem-cell recipients. J Clin Oncol 16:2093–2104

    PubMed  CAS  Google Scholar 

  9. Watanabe T, Dave B, Heimann DG, Jackson JD, Kessinger A, Talmadge JE (1998) Cell adhesion molecule expression on CD34+ cells in grafts and time to myeloid and platelet recovery after autologous stem cell transplantation. Exp Hematol 26:10–18

    PubMed  CAS  Google Scholar 

  10. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG et al (1997) AC133, a novel marker for human haematopoietic stem and progenitor cells. Blood 90:5002–5012

    PubMed  CAS  Google Scholar 

  11. Pasino M, Lanza T, Marotta F, Scarso L, De Biasio P, Amato S et al (2000) Flow cytometric and functional characterisation of AC133(+) cells from human umbilical cord blood. Br J Haematol 108:793–800

    Article  PubMed  CAS  Google Scholar 

  12. Miraglia S, Godfrey W, Yin AH, Atkins K, Warnke R, Holden JT et al (1997) A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterisation and molecular cloning. Blood 90:5013–5021

    PubMed  CAS  Google Scholar 

  13. Peichev M, Naiyer AJ, Pereira D, Zhu Z, Lane WJ, Williams M et al (2000) Expression of VEGFR-2 and AC133 by circulating human CD 34 (+) cells identifies a population of functional endothelial precursors. Blood 95:952–958

    PubMed  CAS  Google Scholar 

  14. Padovan CS, Jahn K, Birnbaum T, Reich P, Sostak P, Strupp M et al (2003) Expression of neuronal markers in differentiated marrow stromal cells and CD133+ stem-like cells. Cell Transplant 12:839–848

    PubMed  Google Scholar 

  15. Bitan M, Shapira MY, Resnick IB, Zilberman I, Miron S, Samuel S et al (2005) Successful transplantation of haploidentically mismatched peripheral blood stem cells using CD133+ purified stem cells. Exp Hematol 33:713–718

    Article  PubMed  CAS  Google Scholar 

  16. Lang P, Bader P, Schumm M, Feuchtinger T, Einsele H, Fuhrer M et al (2004) Transplantation of a combination of CD133+ and CD34+ selected progenitor cells from alternative donors. Br J Hematother Stem Cell Res 12:23–32

    Google Scholar 

  17. Trickett AE, Smith S, Kwan YL (2001) Accurate calculation of blood volume to be processed by aphaeresis to achieve target CD34+ cell numbers or PBPC transplantation. Cytotherapy 3:5–10

    Article  PubMed  CAS  Google Scholar 

  18. Keeney M, Chin-Yee I, Weir K, Popma J, Nayar R, Sutherland DR (1998) Single platform flow cytometric absolute CD34+ cell counts based on the ISHAGE guidelines. International Society of Hematotherapy and Graft Engineering. Cytometry 34:61–70

    Article  PubMed  CAS  Google Scholar 

  19. Sasaki DT, Dumas SE, Engleman EG (1987) Discrimination of viable and non-viable cells using propidium iodide in two color immunofluorescence. Cytometry 8:213–420

    Google Scholar 

  20. Weaver CH, Hazelton B, Birch R, Palmer P, Allen C, Schwartzberg L et al (1995) An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myoablative chemotherapy. Blood 86:3961–3969

    PubMed  CAS  Google Scholar 

  21. Besinger W, Applebaum F, Rowley S, Storb R, Sanders J, Lilleby K et al (1995) Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 13:2547–2555

    Google Scholar 

  22. Haas R, Witt B, Mohle R, Goldschmidt H, Hohaus S, Fruehauf S et al (1995) Sustained long-term haematopoiesis after myeloablative therapy with peripheral blood progenitor support. Blood 85:3754–3761

    PubMed  CAS  Google Scholar 

  23. Ketterer N, Salles G, Raba M, Espinouse D, Sonet A, Tremisi P et al (1998) High CD34(+) counts decrease hematological toxicity of autologous peripheral blood progenitor cell transplantation. Blood 91:3148–3155

    PubMed  CAS  Google Scholar 

  24. Jansen J, Thompson JM, Dugan MJ, Nolan P, Weimann MC, Birhiray R et al (2002) Peripheral blood progenitor cell transplantation. Ther Apher 6:5–14

    Article  PubMed  Google Scholar 

  25. Olivieri A, Offidani M, Montanari M, Ciniero L, Ombrosi L, Masia CM et al (1998) Factors affecting haemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Haematologica 83:329–337

    PubMed  CAS  Google Scholar 

  26. Tricot G, Jagannath D, Nelson J, Tindle S, Miller L, Cheson B et al (1995) Peripheral blood stem cell transplants for multiple myeloma: identification of favourable variables for rapid engraftment in 225 patients. Blood 85:588–596

    PubMed  CAS  Google Scholar 

  27. Yang H, Acker JP, Cabuhat M, Letcher B, Larratt L, McGann LE (2005) Association of post-thaw viable CD34+cells and CFU-GM with time to haematopoietic engraftment. Bone Marrow Transplant 35:881–887

    Article  PubMed  CAS  Google Scholar 

  28. Matsumoto K, Yasui K, Yamashita N, Horie Y, Yamada T, Tani Y et al (2000) In vitro proliferation potential of AC133 positive cells in peripheral blood. Stem Cells 18:196–203

    Article  PubMed  CAS  Google Scholar 

  29. Kuci S, Wessels JT, Buhring HJ, Schilbach K, Schumm M, Seitz G et al (2003) Identification of a novel class of human adherent CD34-stem cells that give rise to SCID-repopulating cells. Blood 101:869–876

    Article  PubMed  CAS  Google Scholar 

  30. Hess DA, Wirthlin L, Craft TP, Herrbrich PE, Hohm SA, Lahey R et al (2006) Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoeitic stem cells. Blood 107:2162–2169

    Article  PubMed  CAS  Google Scholar 

  31. Lefrere F, Delarue R, Levy V, Damaj G, Tu A, Porcher R et al (2002) High dose-CD34+cells are not clinically relevant in reducing cytopenia and blood component consumption following myeloablative therapy and peripheral blood progenitor cell transplantation as compared with standard dose. Transfusion 42:443–450

    Article  PubMed  CAS  Google Scholar 

  32. Hass R, Mohle R, Fruhauf S et al (1994) Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 83:3787–3794

    Google Scholar 

Download references

Acknowledgement

Dr. Alhossain Abdallah and Dr. Freda Passam, St. George Hospital Haematology registrar and visiting staff specialist, respectively, for the statistical correlation and helpful discussions. Thanks also to Sue Smith for her technical assistance and helpful discussions with the flow cytometry.

Author information

Authors and Affiliations

  1. Department of Clinical Haematology, Bone Marrow Transplant Laboratory, St. George Hospital, Kogarah, 2217, Sydney, NSW, Australia

    C. Hicks, R. Wong & A. Manoharan

  2. Department of Haematology, South East Area Laboratory Services, Sydney, Australia

    Y. L. Kwan

Authors
  1. C. Hicks
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. R. Wong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Manoharan
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y. L. Kwan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Hicks.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hicks, C., Wong, R., Manoharan, A. et al. Viable CD34+/CD133+ blood progenitor cell dose as a predictor of haematopoietic engraftment in multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation. Ann Hematol 86, 591–598 (2007). https://doi.org/10.1007/s00277-007-0297-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-007-0297-3

Keywords

Search

Navigation